# Exploring the Preventive Effect of Mitochondrial Protective Agent Idebenone on Post-stroke Epilepsy

> **NCT05987397** · PHASE4 · UNKNOWN · sponsor: **Xiangya Hospital of Central South University** · enrollment: 2700 (estimated)

## Conditions studied

- Post Stroke Epilepsy

## Interventions

- **DRUG:** idebenone 30 mg for 14 days
- **DRUG:** idebenone 30 mg for 3 months

## Key facts

- **NCT ID:** NCT05987397
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-05
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 2700 (ESTIMATED)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05987397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05987397, "Exploring the Preventive Effect of Mitochondrial Protective Agent Idebenone on Post-stroke Epilepsy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05987397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*